Case report: Hyperacute rejection of living relative kidney transplantation caused by colony-stimulating factor 2 antibodies

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology Pub Date : 2025-09-02 DOI:10.1016/j.trim.2025.102285

Qixuan Li , Zhaoying Pang , Meng Yang , Lunli Xiang , Xulian Hu , Qin Yang , Hongwen Zhao , Jie Li , Xiaosong Xu

{"title":"Case report: Hyperacute rejection of living relative kidney transplantation caused by colony-stimulating factor 2 antibodies","authors":"Qixuan Li , Zhaoying Pang , Meng Yang , Lunli Xiang , Xulian Hu , Qin Yang , Hongwen Zhao , Jie Li , Xiaosong Xu","doi":"10.1016/j.trim.2025.102285","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Kidney transplantation (KT) stands as a highly effective, life-saving intervention for patients with end-stage renal disease, offering substantial improvements in both quality of life and long-term survival. However, one of the most critical challenges that can arise in this procedure is hyperacute rejection (HR). This severe immune response occurs almost immediately after transplantation and can place the patient at a heightened risk of serious complications and even drastically jeopardizes the survival of the transplanted kidney. This study reports a case of HR mediated by colony-stimulating factor 2 (CSF2) antibodies following living-related KT, elaborates on its clinical features, diagnostic workflow, and therapeutic management, and analyzes the role of CSF2 antibodies in KT-related immunity. The findings aim to provide clinical reference for optimizing HR prevention and management in KT practice.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102285"},"PeriodicalIF":1.4000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0966327425001133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Kidney transplantation (KT) stands as a highly effective, life-saving intervention for patients with end-stage renal disease, offering substantial improvements in both quality of life and long-term survival. However, one of the most critical challenges that can arise in this procedure is hyperacute rejection (HR). This severe immune response occurs almost immediately after transplantation and can place the patient at a heightened risk of serious complications and even drastically jeopardizes the survival of the transplanted kidney. This study reports a case of HR mediated by colony-stimulating factor 2 (CSF2) antibodies following living-related KT, elaborates on its clinical features, diagnostic workflow, and therapeutic management, and analyzes the role of CSF2 antibodies in KT-related immunity. The findings aim to provide clinical reference for optimizing HR prevention and management in KT practice.

查看原文本刊更多论文

集落刺激因子2抗体致活体亲属肾移植超急性排斥反应一例报告。

背景：肾移植（KT）是一种非常有效的、挽救终末期肾病患者生命的干预措施，在生活质量和长期生存方面都有实质性的改善。然而，在这个过程中可能出现的最关键的挑战之一是超急性排斥反应（HR）。这种严重的免疫反应几乎在移植后立即发生，并可能使患者面临严重并发症的高风险，甚至严重危及移植肾脏的存活。本研究报道一例集落刺激因子2 （colony stimulating factor 2, CSF2）抗体介导的活相关性KT HR，阐述其临床特点、诊断流程和治疗管理，分析CSF2抗体在KT相关免疫中的作用。研究结果旨在为优化KT实践中的人力资源预防和管理提供临床参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplant immunology 医学-免疫学

CiteScore

2.10

自引率

13.30%

发文量

198

审稿时长

48 days

期刊介绍： Transplant Immunology will publish up-to-date information on all aspects of the broad field it encompasses. The journal will be directed at (basic) scientists, tissue typers, transplant physicians and surgeons, and research and data on all immunological aspects of organ-, tissue- and (haematopoietic) stem cell transplantation are of potential interest to the readers of Transplant Immunology. Original papers, Review articles and Hypotheses will be considered for publication and submitted manuscripts will be rapidly peer-reviewed and published. They will be judged on the basis of scientific merit, originality, timeliness and quality.